Instrument Inactif

Communiqués DigiPath, Inc. Other OTC

Actions

DIGP

US2538252022

Appareils, Outillages et articles ménagers

Communiqués

04/06	Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion	AQ
27/04	Trump Psychedelic Executive Order Accelerates Industry Growth	AQ
09/04	Hypha Labs, Inc. (OTCQB:FUNI) Announces Partnership with Mycology Resources, LLC	AQ
15/01	Hypha Labs : Annual Report for Fiscal Year Ending September 30, 2025 (Form 10-K)	PU
12/05/25	Emerging Markets Report: A Milestone for Mycelium	AQ
01/05/25	Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade	AQ
09/04/25	New Mexico Governor Signs Bill Allowing for Psilocybin Use	AQ
17/03/25	Hypha Laboratories Retains Stockhouse for International Awareness Campaign	AQ
12/02/25	Emerging Markets Report: Breakthroughs & Bureaucracy	AQ
17/10/24	Emerging Markets Report: A Mushroom Monster in the Making	AQ
03/10/23	Digipath : Change in Certifying Accountants - Form 8-K	PU
29/08/23	Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30	AQ
05/05/23	Digipath, Inc. Signs Agreement to Sell the Assets of Its Lab Subsidiary	AQ
03/05/23	Digipath : Material Agreement - Form 8-K	PU
03/05/23	DIGIPATH, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/02/23	DIGIPATH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
17/01/23	DIGIPATH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
08/12/22	Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022	AQ
16/08/22	DIGIPATH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
26/07/22	DIGIPATH, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
16/05/22	DIGIPATH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
02/05/22	Digipath Validates and Receives Approval to Use Free DNA Removal to Test for Aspergillus	AQ
04/04/22	Digipath to Provide Product Testing for Redwood Cultivation Products, Including Mike Tyson’s New Ear Shaped Gummies, ‘Mike Bites’	AQ
25/03/22	DIGIPATH, INC. : Other Events (form 8-K)	AQ
01/03/22	Digipath Enters Into Validation Agreement with CASPR Technologies to Determine Efficacy for New Anti-Microbial Product for the Cannabis Industry	AQ